GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations.

ON 146040 is the first dual PI3K and BCR-ABL inhibitor that targets the STAT3 and STAT5 pathways and inhibits PI3K α/δ isoforms with IC50 of 14/20 nM.

Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor with potential antineoplastic activity, it is an orally bioavailable 2-phenylaminopyrimidine derivative.

GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM, respectively.

PF-114 is a Bcr-Abl1 inhbitor.

DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation.

Asciminib is a potent and selective allosteric Bcr-Abl inhibitor and inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.

Nilotinib HCl is a Bcr-Abl inhibitor with IC50 < 30 nM.

GNF-5 is a selective non-ATP competitive inhibitor of Bcr-Abl with IC50 of 220 nM, it's an analogue of GNF-2 with improved pharmacokinetic properties.

GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity (IC50 = 0.14 μM).

Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit.